AAV Vector Exon 2 Skipping for DMD Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophies, such as Duchenne and Becker Muscular Dystrophy, are limited, particularly for patients with duplications of exon 2 in the DMD gene or mutations that maintain a functional IRES sequence within exon 5, as existing gene therapy vectors like AAV have limited packaging capacity and transgene size limitations.
Innovation Solution
The use of a U7snRNA approach within adeno-associated virus (AAV) vectors to induce skipping of DMD exon 2, allowing for the expression of wild-type dystrophin by targeting exon 2 duplications and activating the internal ribosome entry site (IRES) in exon 5, thereby restoring functional dystrophin protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are used for gene therapy, then delivery efficiency is improved, but packaging capacity is limited
Solution Approach 1:
The dystrophin gene is divided into multiple exons, and the therapy targets specific exon skipping (exon 2) to produce a functional truncated protein. This segmentation allows the gene therapy to work within the packaging constraints of AAV vectors by not requiring the entire gene to be packaged.
Solution Approach 2:
The invention extracts and targets specific problematic exons (exon 2 duplications) for skipping, rather than attempting to package or correct the entire dystrophin gene. This extraction approach allows treatment of the specific mutation while working within vector capacity limits.
2Reliability
If exon 2 skipping is induced, then wild-type dystrophin expression is restored, but disease progression delay is limited
Solution Approach 1:
The therapy induces exon skipping and dystrophin expression before significant muscle damage and disease progression occur. By acting preliminarily to restore dystrophin function, the therapy can delay disease progression more effectively than if administered after extensive damage has occurred.
Solution Approach 2:
The invention employs feedback mechanisms to monitor and optimize dystrophin expression levels, adjusting treatment parameters to maximize both expression restoration and long-term disease progression delay. This feedback approach ensures sustained therapeutic effect over time.
3Productivity
If U7snRNA approach is used, then exon skipping efficiency is improved, but treatment complexity increases
Solution Approach 1:
U7snRNA acts as an intermediary molecule that mediates exon skipping by binding to specific sequences and preventing exon inclusion. This intermediary approach achieves high skipping efficiency through a specialized molecular mechanism, though it increases treatment complexity compared to simpler gene replacement approaches.
Data Source
AI summary
Products and methods for treating or preventing muscular dystrophies in patients with duplications of exon (2) in their DMD gene or DMD mutations of any class that maintain a functional IRES sequence within exon (5), and an open reading frame from exon (6) though the end of the DMD gene are provided. Gene therapy vectors, such as adeno-associated virus (AAV) vectors and methods of using these vectors to express DMD are provided. The products and methods are used for treating and/or preventing muscular dystrophies, such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.